Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...

A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

NEJM Publishes New Global Clinical Trial Findings Showing Potential Power of Investigational Medication to Improve ...

Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with ...

For further information, please contact Professor Dr Felix Ringshausen, [email protected], telephone (0511) 532-3595. The original paper ‘Phase 3 Trial of the DPP1 Inhibitor Brensocatib ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 ...

"Brensocatib has the potential to transform the treatment landscape for bronchiectasis and we were pleased to receive the FDA acceptance of our NDA with priority review even earlier than ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses exc ...

Insmed invests heavily in a robust pipeline with multi-billion potential, positioning for future growth. Check out why INSM ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue ...

Pope Francis’ doctor is sharing new details about the 88-year-old pontiff's final hours, including why Francis wasn’t ...